Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256708 | 0.84 | HRH3 (0.44) | HRH3CCR2KCNH2 | |
| SCHEMBL21745492 | 0.84 | HRH3 (0.36) | HRH3 | |
| SCHEMBL20980172 | 0.83 | HRH3 (0.43) | HRH3CCR2KCNH2 | |
| SCHEMBL22893242 | 0.82 | HRH3 (0.47) | HRH3ERBB2EPHA2KDREPHB4 | |
| SCHEMBL24700866 | 0.82 | HRH3 (0.47) | HRH3ERBB2EPHA2KDREPHB4 | |
| SCHEMBL26194411 | 0.81 | HRH3 (0.46) | HRH3ERBB2EPHA2KDREPHB4 | |
| SCHEMBL21157892 | 0.80 | HRH3 (0.45) | HRH3ERBB2EPHA2KDREPHB4 | |
| SCHEMBL18898331 | 0.78 | HRH3 (0.40) | HRH3CCR2KCNH2 | |
| SCHEMBL25872792 | 0.78 | HRH3 (0.44) | HRH3CCR2KCNH2 | |
| SCHEMBL24943355 | 0.78 | HRH3 (0.47) | HRH3ERBB2EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-16 | — | — | US | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | HRH3 3645/4885ERBB2 3331/4885EPHA2 4402/4885 |
| US-10947252-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | HRH3 3645/4885ERBB2 3331/4885EPHA2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.